Lilli Podola

Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial

Friedrich H. Schmitz-Winnenthal, Nicolas Hohmann, Andreas G. Niethammer et al. · OncoImmunology · 2015 · 72 citations · Full text

A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer

Friedrich H. Schmitz-Winnenthal, Nicolas Hohmann, Thomas Schmidt et al. · OncoImmunology · 2017 · 71 citations · Full text

Helminth-Associated Systemic Immune Activation and HIV Co-receptor Expression: Response to Albendazole/Praziquantel Treatment

Mkunde Chachage, Lilli Podola, Petra Clowes et al. · PLoS neglected tropical diseases · 2014 · 32 citations · Full text

Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial

Marc S. Raab, Niels Weinhold, K. Martin Kortüm et al. · Blood · 2024 · 31 citations

VXM01 phase I study in patients with progressive glioblastoma: Final results.

Wolfgang Wick, Antje Wick, Felix Sahm et al. · Journal of Clinical Oncology · 2018 · 16 citations